Gustave Roussy immune score is a prognostic marker in patients with small cell lung cancer undergoing immunotherapy: a real-world retrospective study
BackgroundThe utilization of the Gustave Roussy Immune Score (GRIm-Score) in patient selection for immunotherapy was initially reported. The objective of this retrospective study is to assess the potential of the GRIm-Score, a novel prognostic score based on nutritional and inflammatory markers, as...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-05-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2023.1195499/full |
| _version_ | 1827955461895225344 |
|---|---|
| author | Jian Shangguan Jian Shangguan Xinyi Huang Xinyi Huang Xu Liu Xu Liu Zengfu Zhang Xiaodong Zhang Xiaodong Zhang Jinming Yu Dawei Chen |
| author_facet | Jian Shangguan Jian Shangguan Xinyi Huang Xinyi Huang Xu Liu Xu Liu Zengfu Zhang Xiaodong Zhang Xiaodong Zhang Jinming Yu Dawei Chen |
| author_sort | Jian Shangguan |
| collection | DOAJ |
| description | BackgroundThe utilization of the Gustave Roussy Immune Score (GRIm-Score) in patient selection for immunotherapy was initially reported. The objective of this retrospective study is to assess the potential of the GRIm-Score, a novel prognostic score based on nutritional and inflammatory markers, as a prognostic predictor in patients with small cell lung cancer (SCLC) undergoing immunotherapy.MethodsThis retrospective study conducted at a single center included 159 patients with SCLC who received immunotherapy. The objective of the study was to investigate potential differences in overall survival (OS) and progression-free survival (PFS) among patients stratified by their GRIm-Score, utilizing the Kaplan–Meier survival analysis and the log-rank test. The final independent prognostic factors were identified through both propensity score matching (PSM) analysis and multivariable Cox proportional hazards regression analysis.ResultsOur analysis of the 159 patients revealed that there was a significant decrease in both OS and PFS with each increase in the GRIm-Score group, displaying a stepwise pattern. Moreover, even after conducting PSM analysis, the significant associations between the modified three-category risk scale-based GRIm-Score and survival outcomes remained significant. Both the total cohort and PSM cohort were subjected to multivariable analysis, which demonstrated that the three-category risk assessment-based GRIm-Score was a valuable predictor of both OS and PFS.ConclusionsIn addition, the GRIm-Score may serve as a valuable and non-invasive prognostic predictor for SCLC patients undergoing PD1/PD-L1 immunotherapy. |
| first_indexed | 2024-04-09T14:47:12Z |
| format | Article |
| id | doaj.art-e3786df11c124a38a3b92d54daf1eafa |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-04-09T14:47:12Z |
| publishDate | 2023-05-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-e3786df11c124a38a3b92d54daf1eafa2023-05-02T13:39:02ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2023-05-011310.3389/fonc.2023.11954991195499Gustave Roussy immune score is a prognostic marker in patients with small cell lung cancer undergoing immunotherapy: a real-world retrospective studyJian Shangguan0Jian Shangguan1Xinyi Huang2Xinyi Huang3Xu Liu4Xu Liu5Zengfu Zhang6Xiaodong Zhang7Xiaodong Zhang8Jinming Yu9Dawei Chen10Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, ChinaShandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, ChinaDepartment of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, ChinaShandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, ChinaDepartment of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, ChinaShandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, ChinaDepartment of Radiation Oncology, Shandong University Cancer Center, Jinan, Shandong, ChinaDepartment of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, ChinaShandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, ChinaDepartment of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, ChinaDepartment of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, ChinaBackgroundThe utilization of the Gustave Roussy Immune Score (GRIm-Score) in patient selection for immunotherapy was initially reported. The objective of this retrospective study is to assess the potential of the GRIm-Score, a novel prognostic score based on nutritional and inflammatory markers, as a prognostic predictor in patients with small cell lung cancer (SCLC) undergoing immunotherapy.MethodsThis retrospective study conducted at a single center included 159 patients with SCLC who received immunotherapy. The objective of the study was to investigate potential differences in overall survival (OS) and progression-free survival (PFS) among patients stratified by their GRIm-Score, utilizing the Kaplan–Meier survival analysis and the log-rank test. The final independent prognostic factors were identified through both propensity score matching (PSM) analysis and multivariable Cox proportional hazards regression analysis.ResultsOur analysis of the 159 patients revealed that there was a significant decrease in both OS and PFS with each increase in the GRIm-Score group, displaying a stepwise pattern. Moreover, even after conducting PSM analysis, the significant associations between the modified three-category risk scale-based GRIm-Score and survival outcomes remained significant. Both the total cohort and PSM cohort were subjected to multivariable analysis, which demonstrated that the three-category risk assessment-based GRIm-Score was a valuable predictor of both OS and PFS.ConclusionsIn addition, the GRIm-Score may serve as a valuable and non-invasive prognostic predictor for SCLC patients undergoing PD1/PD-L1 immunotherapy.https://www.frontiersin.org/articles/10.3389/fonc.2023.1195499/fullGustave Roussy immune scorepredictive valuesmall cell lung cancerpropensity score matchingsurvival analysis |
| spellingShingle | Jian Shangguan Jian Shangguan Xinyi Huang Xinyi Huang Xu Liu Xu Liu Zengfu Zhang Xiaodong Zhang Xiaodong Zhang Jinming Yu Dawei Chen Gustave Roussy immune score is a prognostic marker in patients with small cell lung cancer undergoing immunotherapy: a real-world retrospective study Frontiers in Oncology Gustave Roussy immune score predictive value small cell lung cancer propensity score matching survival analysis |
| title | Gustave Roussy immune score is a prognostic marker in patients with small cell lung cancer undergoing immunotherapy: a real-world retrospective study |
| title_full | Gustave Roussy immune score is a prognostic marker in patients with small cell lung cancer undergoing immunotherapy: a real-world retrospective study |
| title_fullStr | Gustave Roussy immune score is a prognostic marker in patients with small cell lung cancer undergoing immunotherapy: a real-world retrospective study |
| title_full_unstemmed | Gustave Roussy immune score is a prognostic marker in patients with small cell lung cancer undergoing immunotherapy: a real-world retrospective study |
| title_short | Gustave Roussy immune score is a prognostic marker in patients with small cell lung cancer undergoing immunotherapy: a real-world retrospective study |
| title_sort | gustave roussy immune score is a prognostic marker in patients with small cell lung cancer undergoing immunotherapy a real world retrospective study |
| topic | Gustave Roussy immune score predictive value small cell lung cancer propensity score matching survival analysis |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2023.1195499/full |
| work_keys_str_mv | AT jianshangguan gustaveroussyimmunescoreisaprognosticmarkerinpatientswithsmallcelllungcancerundergoingimmunotherapyarealworldretrospectivestudy AT jianshangguan gustaveroussyimmunescoreisaprognosticmarkerinpatientswithsmallcelllungcancerundergoingimmunotherapyarealworldretrospectivestudy AT xinyihuang gustaveroussyimmunescoreisaprognosticmarkerinpatientswithsmallcelllungcancerundergoingimmunotherapyarealworldretrospectivestudy AT xinyihuang gustaveroussyimmunescoreisaprognosticmarkerinpatientswithsmallcelllungcancerundergoingimmunotherapyarealworldretrospectivestudy AT xuliu gustaveroussyimmunescoreisaprognosticmarkerinpatientswithsmallcelllungcancerundergoingimmunotherapyarealworldretrospectivestudy AT xuliu gustaveroussyimmunescoreisaprognosticmarkerinpatientswithsmallcelllungcancerundergoingimmunotherapyarealworldretrospectivestudy AT zengfuzhang gustaveroussyimmunescoreisaprognosticmarkerinpatientswithsmallcelllungcancerundergoingimmunotherapyarealworldretrospectivestudy AT xiaodongzhang gustaveroussyimmunescoreisaprognosticmarkerinpatientswithsmallcelllungcancerundergoingimmunotherapyarealworldretrospectivestudy AT xiaodongzhang gustaveroussyimmunescoreisaprognosticmarkerinpatientswithsmallcelllungcancerundergoingimmunotherapyarealworldretrospectivestudy AT jinmingyu gustaveroussyimmunescoreisaprognosticmarkerinpatientswithsmallcelllungcancerundergoingimmunotherapyarealworldretrospectivestudy AT daweichen gustaveroussyimmunescoreisaprognosticmarkerinpatientswithsmallcelllungcancerundergoingimmunotherapyarealworldretrospectivestudy |